Eschenbach Andrew Von Sells 12,500 Shares of Bausch + Lomb (NYSE:BLCO) Stock

Bausch + Lomb Corporation (NYSE:BLCO) Director Eschenbach Andrew Von sold 12,500 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $16.50, for a total value of $206,250.00. Following the sale, the director directly owned 69,792 shares of the company’s stock, valued at $1,151,568. This represents a 15.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Bausch + Lomb Stock Up 0.1%

BLCO opened at $16.85 on Wednesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.02 and a current ratio of 1.55. Bausch + Lomb Corporation has a fifty-two week low of $13.61 and a fifty-two week high of $18.92. The firm’s fifty day moving average is $16.09 and its 200 day moving average is $16.39. The stock has a market cap of $6.02 billion, a price-to-earnings ratio of -35.11, a price-to-earnings-growth ratio of 0.55 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on BLCO shares. UBS Group assumed coverage on shares of Bausch + Lomb in a report on Thursday, July 30th. They issued a “buy” rating and a $21.00 target price for the company. Weiss Ratings lowered shares of Bausch + Lomb from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. HC Wainwright lifted their price objective on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Citigroup boosted their target price on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, Evercore set a $17.00 target price on shares of Bausch + Lomb in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $18.75.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds have recently added to or reduced their stakes in BLCO. Handelsbanken Fonder AB raised its stake in shares of Bausch + Lomb by 5.3% during the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock valued at $364,000 after acquiring an additional 1,100 shares in the last quarter. Bank of America Corp DE grew its stake in Bausch + Lomb by 16.0% in the first quarter. Bank of America Corp DE now owns 65,765 shares of the company’s stock worth $1,046,000 after purchasing an additional 9,066 shares in the last quarter. Royal Bank of Canada grew its stake in Bausch + Lomb by 67.1% in the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock worth $58,000 after purchasing an additional 1,468 shares in the last quarter. Whitebox Advisors LLC increased its holdings in Bausch + Lomb by 15.8% during the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after purchasing an additional 150,641 shares during the period. Finally, Sei Investments Co. increased its holdings in Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock worth $2,214,000 after purchasing an additional 69,633 shares during the period. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.